Source:http://linkedlifedata.com/resource/pubmed/id/10854947
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
9
|
pubmed:dateCreated |
2000-8-3
|
pubmed:abstractText |
The aim of this study was to determine the prevalence, severity and correlates of fatigue in a convenience sample of outpatients with prostate cancer prior to and following 3-months treatment with first-line hormone therapy (cyproterone acetate and goserelin). 'Severe fatigue' in the patients (n=62) was defined as a score on the Fatigue Severity Scale (FSS) greater than the 95th percentile of a group of elderly volunteers without cancer. Subjects also completed other questionnaires about fatigue and about quality of life, anxiety/depression and personality. Subjects underwent a nutritional assessment, tests of voluntary muscle function and attention. The prevalence of 'severe fatigue' at baseline was 8/58 (14%). Median FSS scores increased significantly after 3 months treatment. On multivariate analysis psychological distress explained 28% of the variance in fatigue scores. Treatment was associated with a reduction in voluntary muscle function, loss of muscle bulk, a decline in virility and potency, an improvement in pain and a reduction in nausea/vomiting. Fatigue is an important but under-recognised side-effect of hormone therapy.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0959-8049
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
36
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1134-41
|
pubmed:dateRevised |
2006-4-24
|
pubmed:meshHeading |
pubmed-meshheading:10854947-Aged,
pubmed-meshheading:10854947-Aged, 80 and over,
pubmed-meshheading:10854947-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10854947-Cyproterone Acetate,
pubmed-meshheading:10854947-Fatigue,
pubmed-meshheading:10854947-Female,
pubmed-meshheading:10854947-Goserelin,
pubmed-meshheading:10854947-Humans,
pubmed-meshheading:10854947-Male,
pubmed-meshheading:10854947-Middle Aged,
pubmed-meshheading:10854947-Prostate-Specific Antigen,
pubmed-meshheading:10854947-Prostatic Neoplasms,
pubmed-meshheading:10854947-Quality of Life,
pubmed-meshheading:10854947-Questionnaires,
pubmed-meshheading:10854947-Regression Analysis,
pubmed-meshheading:10854947-Severity of Illness Index
|
pubmed:year |
2000
|
pubmed:articleTitle |
Fatigue in patients with prostate cancer receiving hormone therapy.
|
pubmed:affiliation |
Department of Palliative Medicine, The Royal Marsden NHS Trust, Downs Road, Surrey SM2 5PT, Sutton, UK. paddys@trinityhospice.org.uk
|
pubmed:publicationType |
Journal Article
|